MOUNTAIN VIEW, Calif., March 30 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, and Servier Laboratories Ltd, the British subsidiary of The Servier Research Group, today announced the deployment of the new IVIVC Toolkit(TM) for WinNonlin(R). The IVIVC Toolkit is an optional add-on to WinNonlin that extends its capabilities beyond pharmacokinetic, pharmacodynamic, and non-compartmental analysis to the development and application of in vitro-in vivo correlations. Pharsight solicited input from leading scientists in the industry, including those at Servier, to help guide development of the software.
Leveraging WinNonlin’s powerful modeling engine, the IVIVC Toolkit allows scientists to build customized models to relate a drug formulation’s dissolution characteristics to the in vivo pharmacokinetic (drug concentration) profile. A validated IVIVC can be used to help predict in vivo behavior of a formulation to assess the likelihood of success before entering it in a biostudy. With the IVIVC Wizard(TM) (provided as part of the IVIVC Toolkit) scientists can quickly explore their data and find a suitable model. “The IVIVC Toolkit represents a great step forward in the science of in vitro - in vivo correlation. Servier expects to make extensive use of IVIVC Toolkit for formulation development as well as regulatory filings,” said Theresa Shepard, General Manager of Servier Research and Development.
About the IVIVC Toolkit for WinNonlin
The IVIVC Toolkit expands on WinNonlin’s deconvolution capabilities, while adding convolution, and IVIVC specific analysis plots. In addition to providing tools for scientists to use in their analyses, the IVIVC Toolkit contains an “IVIVC Wizard” that expedites the process by providing a point and click interface for IVIVC creation, evaluation and utilization. The IVIVC Wizard also manages the data and workflow, allowing the project files to be shared amongst various working groups while keeping track of the status of the work.
In conjunction with Pharsight’s Knowledgebase Server (PKS(TM)) the IVIVC Toolkit can be used as part of a workflow compliant with CFR 21 part 11.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Forward Looking Statements
The statements in this press release related to the design and performance of the Pharsight WinNonlin and the IVIVC Toolkit for WinNonlin products are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight’s expectations due to a variety of factors, including customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company’s most recent Form 10-Q filed with the Securities and Exchange Commission on February 12, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.
Registered Trademarks and Trademarks
Pharsight, Pharsight Knowledgebase Server, WinNonlin, IVIVC Toolkit and IVIVC Wizard are registered trademarks or trademarks of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk or Jennifer Beugelmans, +1-646-201-5447,or media, Steve DiMattia, +1-646-201-5445, all of EVC Group for PharsightCorporation
Web site: http://www.pharsight.com//
